STOCKHOLM, SE — November 11, 2025 — Leads & Copy — AlzeCure Pharma AB (publ) (FN STO:ALZCUR) has released its interim report for January-September 2025, now accessible on the company’s website.
CEO Martin Jönsson noted that the third quarter was active for AlzeCure Pharma, with several key developments. In July, the company obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its pain drug Painless ACD440, intended for treating the rare disease erythromelalgia. This designation provides incentives, such as market exclusivity and assistance in the drug development process.
AlzeCure successfully completed a rights issue, raising SEK 48.5 million, which was backed by major shareholders, the Board of Directors, and the management group through subscription commitments. The rights issue was oversubscribed to 212%, resulting in total proceeds of SEK 58.5 million, inclusive of an overallotment option of SEK 10 million. Jönsson expressed gratitude to participants for their confidence in the company’s plans.
The company also presented and published new data related to its pain projects ACD440 and TrkA-NAM. Dr. Cecilia Wadell was appointed as Head of Development, bringing experience in AlzeCure’s therapeutic areas. Dr. Wadell will lead the company’s development efforts.
Key financial figures for July-September 2025 include net sales of SEK 0 thousand (compared to SEK 0 thousand in the same period the previous year) and earnings of SEK -10,025 thousand (compared to SEK -7,474 thousand the previous year). Earnings per share, basic, were SEK -0.09 (same as the previous year). Cash flow from operating activities totaled SEK -7,619 thousand (compared to SEK -8,067 thousand the previous year). Total assets at the end of the period amounted to SEK 66,591 thousand (compared to SEK 47,554 thousand the previous year), and cash and cash equivalents totaled SEK 59,190 thousand (compared to SEK 39,187 thousand the previous year).
For the period of January-September 2025, net sales also totaled SEK 0 thousand (same as the previous year). Earnings were SEK -29,912 thousand (compared to SEK -25,994 thousand the previous year), with earnings per share, basic, at SEK -0.31 (compared to SEK -0.35 the previous year). Cash flow from operating activities totaled SEK -26,012 thousand (compared to SEK -26,819 thousand the previous year). Total assets and cash and cash equivalents at the end of the period mirrored the figures for July-September.
AlzeCure Pharma AB (publ) acquired a newly formed subsidiary at the end of September 2025 to prepare the Group structure for potential future needs. This subsidiary is currently dormant, with all business activities conducted by the parent company.
Significant events during July-September 2025 included the approval of the new share issue at an extraordinary general meeting on July 2, the FDA granting Orphan Drug Designation to ACD440 on July 15, and the presentation of the Rights Issue outcome on July 24. Also in July, the company published a new scientific article presenting results from the Phase IIa clinical trial with ACD440 in patients with chronic peripheral neuropathic pain. In August, Cecilia Wadell was appointed as the new Head of Development, and in September, results for TrkA-NAM ACD137 and ACD440 were presented at the NeuPSIG pain conference in Berlin.
Significant events during January-June 2025 included an EU grant for a Phase II clinical trial of NeuroRestore ACD856 for Alzheimer’s disease, published a new scientific article demonstrating the unique mechanism of action behind Alzstatin and the presentation of new preclinical data for NeuroRestore ACD856 at the international Alzheimer’s and Parkinson’s Disease (AD/PD) conference in Vienna.
Contact:
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease. NeuroRestore has received an EU grant from the European Innovation Council and is being prepared for phase 2. Alzstatin focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease. Painless contains two projects: ACD440, which is a drug candidate for the treatment of neuropathic pain with positive phase 2 results and orphan drug designation from the FDA for the rare disease erythromelalgia, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.
The full report is attached as PDF and is available on the company’s website: www.alzecurepharma.com/en/section/investors/financial-reports/
Source: AlzeCure Pharma
